NCT06170242View on ClinicalTrials.gov

A Controlled Phase 2a Study to Evaluate the Efficacy of EDP-323 Against Respiratory Syncytial Virus Infection in a Virus Challenge Model

PHASE2CompletedINTERVENTIONAL
Enrollment

142

Participants

Timeline

Start Date

November 20, 2023

Primary Completion Date

June 17, 2024

Study Completion Date

July 12, 2024

Conditions
RSV Infection
Interventions
DRUG

EDP-323 Dose Regimen 1

EDP-323 capsule

DRUG

EDP-323 Dose Regimen 2

EDP-323 capsule

DRUG

Placebo

Placebo capsule

Trial Locations (1)

Unknown

hVIVO Services Limited, London

Sponsors
All Listed Sponsors
collaborator

hVIVO Services Limited

INDUSTRY

lead

Enanta Pharmaceuticals, Inc

INDUSTRY